← Back to Search

Antioxidant

Lipoic Acid and Prevention of Heart Disease

Phase 2 & 3
Waitlist Available
Led By Gerd Bobe, PhD
Research Sponsored by Oregon State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial will test whether R-alpha lipoic acid supplements can help reduce obesity risk factors.

Eligible Conditions
  • Femoral Artery Disease
  • Atherosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Lipoic AcidActive Control1 Intervention
600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
Group II: PlaceboPlacebo Group1 Intervention
Placebo two caps every morning on empty stomach

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER
1,008 Previous Clinical Trials
7,414,209 Total Patients Enrolled
National Center for Complementary and Integrative Health (NCCIH)NIH
867 Previous Clinical Trials
674,871 Total Patients Enrolled
Oregon State UniversityLead Sponsor
50 Previous Clinical Trials
8,334 Total Patients Enrolled
Gerd Bobe, PhDPrincipal InvestigatorOregon State University
1 Previous Clinical Trials
50 Total Patients Enrolled
Jonathan Q Purnell, MDPrincipal InvestigatorOregon Health and Science University
2 Previous Clinical Trials
66 Total Patients Enrolled
~6 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top